What Is the Evidence for Current Ataxia Treatments?

The American Academy of Neurology guideline subcommittee reviewed the evidence.

Sponsoring Organization: The guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology

Target Population: Patients with cerebellar motor dysfunction and ataxia

A subcommittee of the American Academy of Neurology reviewed the current evidence on the treatment of cerebellar motor dysfunction and ataxia.

For episodic ataxia type 2, 4-aminopyridine (15 mg/day) “probably reduces” frequency of ataxia attacks (based on 1 Class I study lasting 3 months).
For ataxia of mixed etiology, riluzole “probably improves” ataxia signs (1 Class I study lasting 8 weeks).
For Friedreich ataxia or spinocerebellar ataxia (SCA), riluzole “probably improves” ataxia signs (1 Class I study …

Disclosures

Consultant/Advisory BoardParkinson’s Foundation; Tourette Association of America

Speaker’s BureauMedscape/WebMD CME, Movement Disorders Society CME, American Academy of Neurology CME

RoyaltiesBooks4Patients; Demos; Cambridge; Taylor and Francis; Robert Rose; Public Affairs

Grant/Research SupportNational Institutes of Health; Parkinson’s Foundation; Tourette Association of America; University of Florida Foundation

Editorial BoardsTremor and Other Hyperkinetic Movements; JAMA Neurology